| Stephanie Anne Hoefle, MD | |
|
700 E Sonterra Blvd Ste 202, San Antonio, TX 78258-4386 | |
| (210) 496-7999 | |
| (210) 494-1666 |
| Full Name | Stephanie Anne Hoefle |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 700 E Sonterra Blvd Ste 202, San Antonio, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073509220 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Medical Center | San antonio, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhs Physicians Network Inc | 7315019593 | 585 |
News Archive
UCLA researchers found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.
Inovio Pharmaceuticals, Inc. today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 4 days ago
| Entity Name | Stone Oak Family Doctors Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295875052 PECOS PAC ID: 5496724593 Enrollment ID: O20040927000309 |
News Archive
UCLA researchers found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.
Inovio Pharmaceuticals, Inc. today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 4 days ago
| Entity Name | Bhs Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598958431 PECOS PAC ID: 7315019593 Enrollment ID: O20080703000069 |
News Archive
UCLA researchers found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.
Inovio Pharmaceuticals, Inc. today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Anne Hoefle, MD 700 E Sonterra Blvd Ste 202, San Antonio, TX 78258-4386 Ph: (210) 496-7999 | Stephanie Anne Hoefle, MD 700 E Sonterra Blvd Ste 202, San Antonio, TX 78258-4386 Ph: (210) 496-7999 |
News Archive
UCLA researchers found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.
Inovio Pharmaceuticals, Inc. today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 4 days ago
Dr. Obinna C. Uzowulu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22250 Bulverde Rd, Suite 111, San Antonio, TX 78261 Phone: 210-899-4490 Fax: 210-592-8195 | |
Dr. Salima Jaffer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22800 Bulverde Rd Apt 2202, San Antonio, TX 78261 Phone: 210-878-4033 | |
David A. Ramos, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Nogalitos, Suite 105, San Antonio, TX 78225 Phone: 210-533-0257 Fax: 210-534-0890 | |
Patricia May B. Lacsina, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 903 W Martin St, San Antonio, TX 78207 Phone: 210-358-3441 Fax: 210-358-5944 | |
Adriana S Sanchez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9000 | |
Dr. Aneela N. Hussain, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 4610 E Southcross Blvd, San Antonio, TX 78222 Phone: 210-648-1491 | |
Javier C Bocanegra, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1616 Callaghan Rd, San Antonio, TX 78228 Phone: 210-435-1218 Fax: 210-435-3162 |